


- Amendments to the Claims -


1. (Currently amended) An inhaled combination of (a) a selective PDE4 inhibitor of the formula (I)



or a pharmaceutically acceptable salt or solvate thereof, wherein:

R¹ is H, (C₁-C₆) alkyl, (C₁-C₆) alkoxy, (C₂-C₄) alkenyl, phenyl, -N(CH₃)₂, (C₃-C₆) cycloalkyl, (C₃-C₆) cycloalkyl(C₁-C₃) alkyl or (C₁-C₆) acyl, wherein the alkyl, phenyl or alkenyl groups may be substituted with up to two -OH, (C₁-C₃) alkyl, or -CF₃ groups or up to three halogens;

R² and R³ are each independently selected from the group consisting of H, (C₁-C₁₄) alkyl, (C₁-C₇) alkoxy(C₁-C₇) alkyl, (C₂-C₁₄) alkenyl, (C₃-C₇) cycloalkyl, (C₃-C₇) cycloalkyl(C₁-C₂) alkyl, a saturated or unsaturated (C₄-C₇) heterocyclic(CH₂)_n group wherein n is 0, 1 or 2, containing as the heteroatom one or two of the group consisting of oxygen, sulfur, sulfonyl, nitrogen and NR⁴ where R⁴ is H or (C₁-C₄) alkyl; or a group of the Formula (II):



(II)

wherein a is an integer from 1 to 5; b and c are 0 or 1; R⁵ is H, -OH, (C₁-C₅) alkyl, (C₂-C₅) alkenyl, (C₁-C₅) alkoxy, (C₃-C₆) cycloalkoxy, halogen, -CF₃, -CO₂R⁶, -CONR⁶R⁷, -NR⁶R⁷, -NO₂, or -SO₂NR⁶R⁷ wherein R⁶ and R⁷ are each independently H, or (C₁-C₄) alkyl; Z is -O-, -S-, -SO₂-, -CO- or -N(R⁸)- wherein R⁸ is H or (C₁-C₄) alkyl; and Y is (C₁-C₅) alkylene or (C₂-C₆) alkenylene optionally substituted with up to two (C₁-C₇) alkyl or (C₃-C₇) cycloalkyl groups; wherein each of the alkyl, alkenyl, cycloalkyl, alkoxyalkyl or heterocyclic groups may be substituted with 1 to 14, preferably 1 to 5, (C₁-C₂) alkyl, CF₃, or halo groups; and

R⁹ and R¹⁰ are each independently selected from the group consisting of H, (C₁-C₆) alkyl, (C₁-C₆) alkoxy, (C₆-C₁₀) aryl and (C₆-C₁₀) aryloxy;
and (b) an adrenergic β2 receptor agonist.

2. (Currently amended) A combination of as claimed in claim 1 wherein R¹ is methyl, ethyl or isopropyl.

3. (Currently amended) A combination of as claimed in claim 1 or claim 2 wherein R³ is (C₁-C₆) alkyl, (C₂-C₆) alkenyl, (C₃-C₇) cycloalkyl, (C₃-C₇)cycloalkyl(C₁-C₆)alkyl or phenyl optionally substituted with 1 or 2 of the group consisting of H, -OH, (C₁-C₅) alkyl, (C₂-C₅) alkenyl, (C₁-C₅) alkoxy, halogen, trifluoromethyl, -CO₂R⁶, -CONR⁶R⁷, -NR⁶R⁷, -NO₂ or -SO₂NR⁶R⁷ wherein R⁶ and R⁷ are each independently H or (C₁-C₄) alkyl.

4. (Currently amended) A combination of claim 1 as claimed in any one of the preceding claims wherein the selective PDE4 inhibitor of the formula (I) is selected from:

9-cyclopentyl-5,6-dihydro-7-ethyl-3-phenyl-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclophenyl-5,6-dihydro-7-ethyl-3-(furan-2-yl)-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-pyridyl)-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(4-pyridyl)-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(3-thienyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

3-benzyl-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-propyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

3,9-dicyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(1-methylcyclohex-1-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

3-(*tert*-butyl)-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-methylphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-methoxyphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(thien-2-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

3-(2-chlorophenyl)-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-iodophenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-trifluoromethylphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine; and or

5,6-dihydro-7-ethyl-9-(4-fluorophenyl)-3-(1-methylcyclohex-1-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine; or a pharmaceutically acceptable salt or solvate thereof.

5. (Currently amended) A combination of as claimed in claim 4 wherein the selective PDE4 inhibitor of the formula (I) is selected from 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-thienyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine and or 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(*tert*-butyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine and the or a pharmaceutically acceptable salt or solvate thereof.

6. (Currently amended) A combination of as claimed in any one of the preceding claims 1 - 5 wherein the adrenergic β_2 receptor agonist is selected from salmeterol, formoterol and the or a pharmaceutically acceptable salt or solvate thereof.

7. (Currently amended) A combination as claimed in of claim 1 wherein:
the selective PDE4 inhibitor of the formula (I) is 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-thienyl)-9*H*-pyrazolo[3,4-c]-1,2,4-triazolo[4,3- α]pyridine, or a pharmaceutically acceptable salt or solvate thereof, and the adrenergic β 2 receptor agonist is salmeterol, or a pharmaceutically acceptable salt or solvate thereof;
the selective PDE4 inhibitor of the formula (I) is 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-thienyl)-9*H*-pyrazolo[3,4-c]-1,2,4-triazolo[4,3- α]pyridine, or a pharmaceutically acceptable salt or solvate thereof, and the adrenergic β 2 receptor agonist is formoterol, or a pharmaceutically acceptable salt or solvate thereof;
the selective PDE4 inhibitor of the formula (I) is 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(*tert*-butyl)-9*H*-pyrazolo[3,4-c]-1,2,4-triazolo[4,3- α]pyridine, or a pharmaceutically acceptable salt or solvate thereof, and the adrenergic β 2 receptor agonist is salmeterol, or a pharmaceutically acceptable salt or solvate thereof; or
the selective PDE4 inhibitor of the formula (I) is 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(*tert*-butyl)-9*H*-pyrazolo[3,4-c]-1,2,4-triazolo[4,3- α]pyridine, or a pharmaceutically acceptable salt or solvate thereof, and the adrenergic β 2 receptor agonist is formoterol, or a pharmaceutically acceptable salt or solvate thereof.

8. (Canceled)

9. (Canceled)

10. (Currently amended) A An inhalable pharmaceutical composition comprising a selective PDE4 inhibitor of the formula (I), as defined in of claim 1, an adrenergic β 2 receptor agonist and a pharmaceutically acceptable excipient, diluent or carrier, for administration by the inhaled route in the treatment of an obstructive airways or other inflammatory disease.

11. (Canceled)

12. (Canceled)

13. (Canceled)

14. (Currently amended) A method of treating of an obstructive airways or other inflammatory disease comprising administering simultaneously, sequentially or separately, by the inhaled route, to a mammal in need of such treatment, an effective amount of a

selective PDE4 inhibitor of the formula (I),~~as defined in~~ of claim 1, and an adrenergic β 2 receptor agonist.

15. (Canceled)

16. (Currently amended) An inhalation device for simultaneous, sequential or separate administration of a selective PDE4 inhibitor of the formula (I),~~as defined in~~ of claim 1, and an adrenergic β 2 receptor agonist in the treatment of an obstructive airways or other inflammatory disease.

17. (Canceled)

18. (New) A pharmaceutical composition of claim 10 wherein the selective PDE4 inhibitor of the formula (I) is:

9-cyclopentyl-5,6-dihydro-7-ethyl-3-phenyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(furan-2-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-pyridyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(4-pyridyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(3-thienyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

3-benzyl-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-propyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

3,9-dicyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(1-methylcyclohex-1-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

3-(*tert*-butyl)-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-methylphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-methoxyphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(thien-2-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

3-(2-chlorophenyl)-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-iodophenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-trifluoromethylphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine; or

5,6-dihydro-7-ethyl-9-(4-fluorophenyl)-3-(1-methylcyclohex-1-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine; or a pharmaceutically acceptable salt thereof.

19. (New) A pharmaceutical composition of claim 18 wherein the selective PDE4 inhibitor of the formula (I) is 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-thienyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine or 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(*tert*-butyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine or a pharmaceutically acceptable salt thereof.

20. (New) A pharmaceutical composition of claim 18 wherein the adrenergic $\beta 2$ receptor agonist is selected from salmeterol, formoterol or a pharmaceutically acceptable salt thereof.

21. (New) A pharmaceutical composition of claim 18 wherein:
the selective PDE4 inhibitor of the formula (I) is 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-thienyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine, or a pharmaceutically acceptable salt thereof, and the adrenergic $\beta 2$ receptor agonist is salmeterol, or a pharmaceutically acceptable salt thereof;
the selective PDE4 inhibitor of the formula (I) is 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-thienyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine, or a pharmaceutically acceptable salt thereof, and the adrenergic $\beta 2$ receptor agonist is formoterol, or a pharmaceutically acceptable salt thereof;
the selective PDE4 inhibitor of the formula (I) is 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(*tert*-butyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine, or a pharmaceutically acceptable salt

thereof, and the adrenergic β 2 receptor agonist is salmeterol, or a pharmaceutically acceptable salt thereof; or

the selective PDE4 inhibitor of the formula (I) is 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(*tert*-butyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine, or a pharmaceutically acceptable salt thereof, and the adrenergic β 2 receptor agonist is formoterol, or a pharmaceutically acceptable salt thereof.

22. (New) A method of treating of an inflammatory disease in a mammal comprising administering, by the inhaled route, to a mammal in need of such treatment, an effective amount of a selective PDE4 inhibitor of the formula (I) of claim 1, and an adrenergic β 2 receptor agonist.

23. (New) A method of claim 14 or 22 wherein the selective PDE4 inhibitor of the formula (I) is:

9-cyclopentyl-5,6-dihydro-7-ethyl-3-phenyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(furan-2-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-pyridyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(4-pyridyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(3-thienyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

3-benzyl-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-propyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

3,9-dicyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(1-methylcyclohex-1-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

3-(*tert*-butyl)-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-methylphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-methoxyphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(thien-2-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

3-(2-chlorophenyl)-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-iodophenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-trifluoromethylphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine; or

5,6-dihydro-7-ethyl-9-(4-fluorophenyl)-3-(1-methylcyclohex-1-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine; or a pharmaceutically acceptable salt thereof.

24. (New) A method of claim 14 or 22 wherein the selective PDE4 inhibitor of the formula (I) is 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-thienyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine or 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(*tert*-butyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine or a pharmaceutically acceptable salt thereof.

25. (New) A method of claim 14 or 22 wherein the adrenergic β 2 receptor agonist is selected from salmeterol, formoterol or a pharmaceutically acceptable salt thereof.

26. (New) A method of claim 14 or 22 wherein:
the selective PDE4 inhibitor of the formula (I) is 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-thienyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine, or a pharmaceutically acceptable salt thereof, and the adrenergic β 2 receptor agonist is salmeterol, or a pharmaceutically acceptable salt thereof;
the selective PDE4 inhibitor of the formula (I) is 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-thienyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine, or a pharmaceutically acceptable salt thereof, and the adrenergic β 2 receptor agonist is formoterol, or a pharmaceutically acceptable salt thereof;
the selective PDE4 inhibitor of the formula (I) is 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(*tert*-butyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine, or a pharmaceutically acceptable salt thereof, and the adrenergic β 2 receptor agonist is salmeterol, or a pharmaceutically acceptable salt thereof; or

the selective PDE4 inhibitor of the formula (I) is 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(*tert*-butyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine, or a pharmaceutically acceptable salt thereof, and the adrenergic β 2 receptor agonist is formoterol, or a pharmaceutically acceptable salt thereof.

27. (New) A method of any one of claims 14 or 22 wherein said selective PDE4 inhibitor and said adrenergic β 2 receptor agonist are administered simultaneously, sequentially or separately. ✓

28. (New) A method of claim 14 wherein said obstructive airways disease is asthma, acute respiratory distress syndrome, chronic pulmonary inflammatory disease, bronchitis, chronic bronchitis, chronic pulmonary obstructive disease (COPD), silicosis, allergic rhinitis or chronic sinusitis.

29. (New) A method of claim 28 wherein said obstructive airways disease is chronic obstructive pulmonary disease (COPD).

30. (New) A device of claim 16 wherein the selective PDE4 inhibitor of the formula (I) is:

9-cyclopentyl-5,6-dihydro-7-ethyl-3-phenyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(furan-2-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-pyridyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(4-pyridyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(3-thienyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

3-benzyl-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-propyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

3,9-dicyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(1-methylcyclohex-1-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

3-(*tert*-butyl)-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-methylphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-methoxyphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(thien-2-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

3-(2-chlorophenyl)-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-iodophenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-trifluoromethylphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine; or

5,6-dihydro-7-ethyl-9-(4-fluorophenyl)-3-(1-methylcyclohex-1-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine; or a pharmaceutically acceptable salt thereof.

31. (New) A device of claim 16 wherein the selective PDE4 inhibitor of the formula (I) is 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-thienyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine or 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(*tert*-butyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine or a pharmaceutically acceptable salt thereof.

32. A device of claim 16 wherein the adrenergic β 2 receptor agonist is selected from salmeterol, formoterol or a pharmaceutically acceptable salt thereof.

33. A device of claim 16 wherein:

the selective PDE4 inhibitor of the formula (I) is 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-thienyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine, or a pharmaceutically acceptable salt thereof, and the adrenergic β 2 receptor agonist is salmeterol, or a pharmaceutically acceptable salt thereof;

the selective PDE4 inhibitor of the formula (I) is 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-thienyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine, or a pharmaceutically acceptable salt thereof, and the adrenergic β 2 receptor agonist is formoterol, or a pharmaceutically acceptable salt thereof;

the selective PDE4 inhibitor of the formula (I) is 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(*tert*-butyl)-9*H*-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-*α*]pyridine, or a pharmaceutically acceptable salt thereof, and the adrenergic β2 receptor agonist is salmeterol, or a pharmaceutically acceptable salt thereof; or

the selective PDE4 inhibitor of the formula (I) is 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(*tert*-butyl)-9*H*-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-*α*]pyridine, or a pharmaceutically acceptable salt thereof, and the adrenergic β2 receptor agonist is formoterol, or a pharmaceutically acceptable salt thereof.

A Notice of Allowance is courteously solicited.

Respectfully Submitted,

Date: December 16, 2003


Robert T. Ronau
Attorney for Applicants
Reg. No. 36,257

Pfizer Inc.
Patent Department
Eastern Point Road
Groton, Connecticut 06340
860-441-5910